[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537943":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":75,"collaborators":10,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":10,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":10,"studyType":91,"phases":10,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Hospital General de Mexico","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group",null,"Thalidomide 100mg-200mg PO daily alone or in combination with dexamethasone 40mg PO every 24 hours on days 1-4, 8-11 of each cycle.",[13],"Drug: Bortezomib",{"label":15,"type":10,"description":16,"interventionNames":17},"Bortezomib Group","Bortezomib 1.3mg\u002Fm2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (VTD).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Bortezomib","Bortezomib 1.3mg\u002Fm2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)",[15,9],[25],"Intervention Group",[27],{"name":28,"affiliation":29,"role":30},"Adolfo O Martinez Tovar, PhD","Hospital General de México Dr. Eduardo Liceaga","STUDY_DIRECTOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Christian O Ramos Peñafiel, PhD","CONTACT","+52 55 27892000","2020","leukemiachop33@gmail.com",{"name":39,"role":34,"phone":35,"phoneExt":36,"email":40},"Adán G Gallardo Rodriguez, PhD","nutriologo.agallardo8@gmail.com",[42],{"facility":43,"status":44,"city":45,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Hospital General de Mexico Dr. Eduardo Liceaga","RECRUITING","Mexico City","06720","Mexico","MX",{"type":50,"coordinates":51},"Point",[52,53],-99.12766,19.42847,{"lat":53,"lon":52},[56,58,61,64,66,67,69,71,73],{"name":33,"role":34,"phone":57,"phoneExt":10,"email":37},"5523351588",{"name":59,"role":34,"phone":60,"phoneExt":10,"email":40},"Adan G Gallardo Rodriguez","+525584005072",{"name":62,"role":63,"phone":10,"phoneExt":10,"email":10},"Juan M Cano Calderón, MD","SUB_INVESTIGATOR",{"name":65,"role":63,"phone":10,"phoneExt":10,"email":10},"Juan F Zazueta Pozos, MD",{"name":39,"role":63,"phone":10,"phoneExt":10,"email":10},{"name":68,"role":63,"phone":10,"phoneExt":10,"email":10},"Carlos Martínez Murillo, PhD",{"name":70,"role":63,"phone":10,"phoneExt":10,"email":10},"Irma Olarte Carrillo, PhD",{"name":72,"role":63,"phone":10,"phoneExt":10,"email":10},"Adolfo Martínez Tovar, PhD",{"name":33,"role":74,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":74,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Christian Omar Ramos-Peñafiel, MD, PhD","Principal investigator","100537943","two-schemes-response-in-multiple-myeloma-100537943",false,"NCT06284395","Two Schemes Response in Multiple Myeloma","Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study","Inclusion Criteria:\n\n* clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs.\n\nExclusion Criteria:\n\n* Incomplete clinical records\n* Clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues\n* Clinical records of patients who presented severe sepsis before the beginning of either treatment","ALL","18 Years","90 Years",{"count":89,"type":90},83,"ESTIMATED","OBSERVATIONAL","Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.",[94,95],"Response, Acute Phase","Survivorship",[97,21,98,99,100],"Multiple Myeloma","Thalidomide","Acute Phase Response","Survival","2024-09-30",{"date":103,"type":104},"2024-10-02","ACTUAL",{"date":106,"type":104},"2023-11-20",{"date":108,"type":90},"2024-10-30",{"name":5,"class":6},1]